Tide is finally turning for patient access to US biosimilars
Biosimilars continue to gain traction in the U.S. as a result of momentum from policymakers, regulators and others in government to drive patient access to this important category of medicine. The latest example came earlier this month with a significant new rule from the Centers for Medicare and Medicaid Services (CMS).
